FGF-1 vs Palmitoyl Tripeptide-1

Binds all four FGFR subtypes (broadest binding of FGF family). Activates MAPK and PI3K downstream pathways. Promotes fibroblast proliferation, angiogenesis, and hair follicle cycling into anagen phase.

FGF-1 (fibroblast growth factor 1; acidic FGF; aFGF) is an endogenous 155-amino-acid heparin-binding growth factor and the prototypic member of the 22-member FGF family, expressed in diverse tissues where it stimulates cell proliferation, survival, and migration through tyrosine kinase receptor (FGFR1-4) signaling, with particularly important roles in angiogenesis, wound healing, and tissue repair. FGF-1 activates FGFR to initiate MAPK/ERK, PI3K/Akt, and PLCgamma signaling cascades driving endothelial cell sprouting and neovascularization; in ischemic tissues, FGF-1 is a potent inducer of therapeutic angiogenesis, stimulating new vessel formation to restore perfusion in peripheral arterial disease and critical limb ischemia. A Phase 2 randomized controlled trial of intramuscular gene-encoded FGF-1 delivery (NV1FGF, a non-viral plasmid vector) in critical limb ischemia demonstrated improved amputation-free survival in human subjects, providing clinical evidence for FGF-1 pathway activity; this gene therapy approach is distinct from direct recombinant FGF-1 protein administration, and no protein therapy form has completed Phase 3 trials. Recombinant FGF-1 protein has no FDA approval as a standalone therapeutic; the clinical evidence base references gene-encoded delivery rather than the protein itself, and research-grade FGF-1 is used primarily as a cell culture supplement and tissue engineering scaffold factor rather than as a therapeutically administered agent.

Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Palmitoyl Tripeptide-1 (Pal-GHK) is a fatty-acid-conjugated form of the copper-binding tripeptide GHK (glycine-histidine-lysine), widely used in cosmetic formulations targeting skin firmness and matrix support. GHK is a naturally occurring human plasma peptide that modulates collagen and elastin synthesis, matrix remodeling enzyme activity, and antioxidant gene expression. Conjugating GHK to palmitic acid (a fatty acid) significantly improves transdermal penetration, allowing the peptide to reach the fibroblast-rich dermis from topical application — addressing the primary limitation of unmodified GHK, which does not readily cross the stratum corneum barrier. Pal-GHK vs GHK-Cu: Palmitoyl Tripeptide-1 (Pal-GHK) and GHK-Cu (copper peptide) derive from the same GHK tripeptide backbone but are formulated differently. GHK-Cu complexes GHK with copper(II) ions to leverage the copper-mediated wound healing and antioxidant mechanisms of the peptide. Pal-GHK conjugates GHK with palmitic acid for improved dermal penetration without the copper component. Both are used in anti-aging cosmetic formulations; GHK-Cu is used in injectable/serum contexts where copper activity is desired, while Pal-GHK appears predominantly in cosmetic skincare products where lipid-conjugated delivery is the priority. Matrixyl Synthe'6 context: Palmitoyl Tripeptide-1 is a primary active in Sederma's Matrixyl Synthe'6 formulation, which combines six components proposed to support six key structural proteins of the skin matrix: collagen I, III, and IV, fibronectin, laminin-5, and hyaluronic acid. The combination positions Pal-GHK as the collagen-stimulating component within a broader matrix-targeting blend, distinguishing Matrixyl Synthe'6 from the original Matrixyl (palmitoyl pentapeptide-4) and Matrixyl 3000 formulations. Products containing Matrixyl Synthe'6 list palmitoyl tripeptide-1 as an INCI ingredient alongside palmitoyl tetrapeptide-38 and other actives. Research and formulation: In vitro studies on palmitoyl tripeptide-1 show stimulation of collagen I and III synthesis in human fibroblast cultures. Clinical evidence is primarily from manufacturer-sponsored cosmetic studies showing improvements in skin firmness metrics. Palmitoyl Tripeptide-1 is included in the Cosmetics Europe Colipa ingredient database; it is not classified as a drug in any major jurisdiction. Concentrations in cosmetic formulations typically range from 2–5% of the palmitoyl tripeptide-1 ingredient solution (peptide content within the solution is lower, per the Sederma concentrate formulation). It is available exclusively in topical cosmetic form — there is no injectable or clinical application for this compound.